Arista Wealth Management LLC Buys New Holdings in Danaher Corporation $DHR

Key Points

• Arista Wealth Management LLC acquired a new position in Danaher Corporation, purchasing 3,387 shares valued at approximately $669,000 in the second quarter of 2023.
• Danaher's stock received mixed reviews from analysts, with target prices ranging from $205 to $275, and a consensus rating of "Moderate Buy."
• The company recently announced a quarterly dividend of $0.32 per share, scheduled to be paid on October 31st, representing an annualized yield of 0.6%.

Arista Wealth Management LLC purchased a new position in shares of Danaher Corporation (NYSE:DHR - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 3,387 shares of the conglomerate's stock, valued at approximately $669,000.

Other large investors also recently modified their holdings of the company. GHP Investment Advisors Inc. increased its position in Danaher by 396.0% during the 1st quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate's stock worth $25,000 after purchasing an additional 99 shares in the last quarter. Sierra Ocean LLC grew its stake in Danaher by 116.9% during the first quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate's stock worth $29,000 after buying an additional 76 shares during the period. Red Tortoise LLC increased its position in shares of Danaher by 175.0% in the second quarter. Red Tortoise LLC now owns 154 shares of the conglomerate's stock worth $30,000 after acquiring an additional 98 shares in the last quarter. Smallwood Wealth Investment Management LLC acquired a new stake in shares of Danaher in the first quarter worth $31,000. Finally, Dunhill Financial LLC raised its stake in shares of Danaher by 68.4% in the 1st quarter. Dunhill Financial LLC now owns 165 shares of the conglomerate's stock valued at $34,000 after acquiring an additional 67 shares during the period. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, Director Teri List sold 2,778 shares of the stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the sale, the director owned 20,751 shares in the company, valued at $4,379,706.06. This represents a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 11.10% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

DHR has been the subject of a number of research reports. Scotiabank raised shares of Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price target for the company in a research report on Friday, July 11th. Wells Fargo & Company decreased their target price on Danaher from $210.00 to $205.00 and set an "equal weight" rating for the company in a research report on Wednesday, July 23rd. UBS Group dropped their target price on Danaher from $240.00 to $225.00 and set a "buy" rating on the stock in a report on Wednesday, July 23rd. Royal Bank Of Canada set a $241.00 price target on Danaher in a research report on Tuesday, September 2nd. Finally, Redburn Partners set a $220.00 price objective on shares of Danaher in a research report on Wednesday, October 8th. Seventeen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $244.60.

Danaher Trading Up 2.3%

NYSE:DHR opened at $210.86 on Friday. The stock has a market cap of $150.99 billion, a price-to-earnings ratio of 44.86, a price-to-earnings-growth ratio of 2.94 and a beta of 0.77. Danaher Corporation has a one year low of $171.00 and a one year high of $279.41. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.22 and a current ratio of 1.62. The business's 50-day simple moving average is $201.43 and its 200 day simple moving average is $197.23.

Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.64 by $0.16. The company had revenue of $5.94 billion during the quarter, compared to analyst estimates of $5.83 billion. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The firm's revenue for the quarter was up 3.4% compared to the same quarter last year. During the same period last year, the business earned $1.72 EPS. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, sell-side analysts predict that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, September 26th. Danaher's dividend payout ratio is currently 27.23%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.